Andrea Heslin Smiley will serve on the respective Audit and Compensation Committees.
An accomplished Life Sciences industry executive, Andi has 28 years of commercialization and general management experience across numerous senior leadership roles in both public and private companies.
Currently she is the President and CEO of VMS BioMarketing, a high-growth, healthcare services business working to improve patient outcomes by delivering evidence-based engagements to patients, caregivers and healthcare providers through a technology enabled, data driven, clinical educator platform.
Having spent 18 years at Eli Lilly and Company in various business unit leadership roles as well as in management positions across finance, business development, corporate affairs and brand management, Andi brings a wealth of experience in numerous therapeutic areas, deep insight on the patient and provider mindset and extensive knowledge on how to drive sustainable behavior change that enables improvements in medication adherence.
Her P&L leadership over a variety of business units including endocrinology, growth hormone, osteoporosis and women’s health resulted in consistently strong revenue and profit growth, a reflection of her ability to successfully lead the development and execution of biopharmaceutical commercialization strategies. While at Eli Lilly, Andi saw first hand how VMS was one of the few companies that was able to have a direct impact on patients, and recognizing the potential global impact of this type of solution, she became passionate about scaling VMS.
After joining VMS in 2008 to lead the company’s strategic marketing and brand development teams, Andi was named President and CEO in 2011. Since that time, Andi worked to divest VMS lower margin business units, focus the company’s efforts in the adherence market and make several strategic investments in technology, people and infrastructure that has led to multiple years of double digit growth for VMS. Through that growth, Andi has also fostered an inspiring and distinctive company culture that has been recognized many times by Fortune and Great Place to Work.
Andi has received several awards, most recently the PharmaVOICE 100 – One of the 100 most inspiring people in the life sciences industry, PM360 ELITE – Master Educator Award and MM&M Magazine –Hall of Femme. She remains deeply engaged by providing strategic consulting on pre and post commercialization strategies for clients and being a regular speaker and panelist at leading industry conferences.
Beyond her work at VMS, Andi currently serves on the board of directors of Rockwell Medical and is an Advisor for Agent Capital, a leading healthcare venture capital firm. She previously served on Assertio Therapeutics, Zyla Life Sciences, Egalet Corporation and AppianRx. Additionally, she serves on the board of the Indiana Alzheimer’s Association and the Mitch Daniels Leadership Foundation.
Prior to Eli Lilly and Company, Andi worked as a management consultant for Putnam Associates, where she advised brands in the biotech, pharmaceutical, and managed healthcare ﬁelds on product launches and access strategies. She earned her BA in economics from DePauw University where she was an Honors Management Fellow.